191 related articles for article (PubMed ID: 21909128)
1. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
Zhao H; Xi X; Cui L; He W
Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
[TBL] [Abstract][Full Text] [Related]
2. Profiling the pattern of the human T-cell receptor γδ complementary determinant region 3 repertoire in patients with lung carcinoma via high-throughput sequencing analysis.
Chen H; Zou M; Teng D; Hu Y; Zhang J; He W
Cell Mol Immunol; 2019 Mar; 16(3):250-259. PubMed ID: 30886423
[TBL] [Abstract][Full Text] [Related]
3. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody.
Wang Z; Zhang T; Hu H; Zhang H; Yang Z; Cui L; He W
Cancer Lett; 2008 Dec; 272(2):242-52. PubMed ID: 18782650
[TBL] [Abstract][Full Text] [Related]
4. γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.
Gründer C; van Dorp S; Hol S; Drent E; Straetemans T; Heijhuurs S; Scholten K; Scheper W; Sebestyen Z; Martens A; Strong R; Kuball J
Blood; 2012 Dec; 120(26):5153-62. PubMed ID: 23018643
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Chen J; Niu H; He W; Ba D
Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
[TBL] [Abstract][Full Text] [Related]
6. Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta.
Xi X; Guo Y; Chen H; Xu C; Zhang H; Hu H; Cui L; Ba D; He W
J Biol Chem; 2009 Oct; 284(40):27449-55. PubMed ID: 19666468
[TBL] [Abstract][Full Text] [Related]
7. Gammadelta T cells recognize tumor cells via CDR3delta region.
Xu C; Zhang H; Hu H; He H; Wang Z; Xu Y; Chen H; Cao W; Zhang S; Cui L; Ba D; He W
Mol Immunol; 2007 Jan; 44(4):302-10. PubMed ID: 16650897
[TBL] [Abstract][Full Text] [Related]
8. γ9δ2T cell diversity and the receptor interface with tumor cells.
Vyborova A; Beringer DX; Fasci D; Karaiskaki F; van Diest E; Kramer L; de Haas A; Sanders J; Janssen A; Straetemans T; Olive D; Leusen J; Boutin L; Nedellec S; Schwartz SL; Wester MJ; Lidke KA; Scotet E; Lidke DS; Heck AJ; Sebestyen Z; Kuball J
J Clin Invest; 2020 Sep; 130(9):4637-4651. PubMed ID: 32484803
[TBL] [Abstract][Full Text] [Related]
9. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
10. Tandem-epitope peptide: a novel stimulator for gammadeltaT cells in tumor immunotherapy.
He X; Chen H; Wu D; Cui L; He W
Cancer Lett; 2010 Feb; 288(1):86-93. PubMed ID: 19665289
[TBL] [Abstract][Full Text] [Related]
11. The recognition of gammadelta TCR to protein antigen does not depend on the hydrophobic I97 residue of CDR3delta.
Xi X; Cui L; He W
Int Immunol; 2010 Apr; 22(4):299-306. PubMed ID: 20181655
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
13. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy.
Chen H; He X; Wang Z; Wu D; Zhang H; Xu C; He H; Cui L; Ba D; He W
J Biol Chem; 2008 May; 283(18):12528-37. PubMed ID: 18321859
[TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
15. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
16. γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy Adults.
Vyborova A; Janssen A; Gatti L; Karaiskaki F; Yonika A; van Dooremalen S; Sanders J; Beringer DX; Straetemans T; Sebestyen Z; Kuball J
Front Immunol; 2022; 13():915366. PubMed ID: 35874769
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
[TBL] [Abstract][Full Text] [Related]
18. T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor.
Lee YS; Kim TS; Kim DK
BMC Cancer; 2011 Jun; 11():225. PubMed ID: 21649881
[TBL] [Abstract][Full Text] [Related]
19. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
